ReviewInternational journal of molecular sciences2023
Glucagon and Its Receptors in the Mammalian Heart.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Effectiveness of treatments for propranolol toxicity: a systematic review of current approaches and evidence.European journal of clinical pharmacology · 2026Pooled it
- Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.Scientific reports · 2025Trial
- The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction.Medicina (Kaunas, Lithuania) · 2026Review
- Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.Pharmaceutics · 2026Review
- Cardiac neurons expressing a glucagon-like receptor mediate cardiac arrhythmia induced by high-fat diet ineLife · 2026Article
- Inotropic effects of retatrutide in isolated human atrial preparations.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Contractile Effects of Glucagon in Mouse Cardiac Preparations.International journal of molecular sciences · 2025Article
- Contractile effects of retatrutide in isolated mouse atrial preparations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Ubrogepant, erenumab, and eptinezumab antagonize positive inotropic effects of the calcitonin gene-related peptide in the isolated human atrium.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Advances in Insulin Resistance-Molecular Mechanisms, Therapeutic Targets, and Future Directions.International journal of molecular sciences · 2025Article
- Glucagon Can Increase Force of Contraction via Glucagon Receptors in the Isolated Human Atrium.International journal of molecular sciences · 2025Article
- Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control.Frontiers in endocrinology · 2025Review
- Evaluating sex-specific responses to western diet across the lifespan: impact on cardiac function and transcriptomic signatures in C57BL/6J mice at 530 and 640/750 days of age.Cardiovascular diabetology · 2024Article
- GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms.The Journal of endocrinology · 2024Review
- Bisphenol C Induces Cardiac Developmental Defects by Disrupting mEnvironmental science & technology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon exerts effects on the mammalian heart. These effects include alterations in the force of contraction, beating rate, and changes in the cardiac conduction system axis. The cardiac effects of glucagon vary according to species, region, age, and concomitant disease. Depending on the species and region studied, the contractile effects of glucagon can be robust, modest, or even absent. Glucagon is detected in the mammalian heart and might act with an autocrine or paracrine effect on the cardiac glucagon receptors. The glucagon levels in the blood and glucagon receptor levels in the heart can change with disease or simultaneous drug application. Glucagon might signal via the glucagon receptors but, albeit less potently, glucagon might also signal via glucagon-like-peptide-1-receptors (GLP1-receptors). Glucagon receptors signal in a species- and region-dependent fashion. Small molecules or antibodies act as antagonists to glucagon receptors, which may become an additional treatment option for diabetes mellitus. Hence, a novel review of the role of glucagon and the glucagon receptors in the mammalian heart, with an eye on the mouse and human heart, appears relevant. Mouse hearts are addressed here because they can be easily genetically modified to generate mice that may serve as models for better studying the human glucagon receptor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.